21
Nov
2024
Dr. Oz to CMS, Amgen and Pfizer Get New CSOs, & SubQ Keytruda Arrives
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Nov
2024
Speaking Up for Science and Health. Even When Inconvenient
“By their fruits, ye shall know them” –Matthew 7:16 Immediately following the election of Donald Trump, a number of publications asked leaders of the biopharmaceutical industry and investment community to share their thoughts on how his likely policies and appointees to key positions of leadership will affect our industry. Many of these leaders counseled us to “wait and see” before making... Read More
21
Nov
2024
Startup Snapshots: A Tetra-Binder for Obesity, and a ‘Mirror Peptide’ Engine
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Nov
2024
US-China Partnership: Just Hitting its Stride, and Now Threatened
Curon, Chimagen, Hengrui, LaNova…the list goes on of Chinese biotech companies that have recently licensed potential blockbuster drug candidates for cancer, autoimmunity and more to US pharma and biotech companies for further development. Over the past year or so, there has been a dramatic increase in both the number of deals to obtain rights to assets discovered in China, and... Read More
19
Nov
2024
A Tale of Two Neds: Jupiter Debuts with $70M To Invest in Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Nov
2024
Coastal Culture Clash Around AI in Biotech
“Does the crowd understand? Is it East versus West Or man against man? Can any nation stand alone?” Burning Heart, by Survivor – Rocky IV In national politics, the culture wars may pit the coasts against the rest of the country. In biotech, however, the AI culture war seems to pit the coasts against each other. Consider this recent LinkedIn... Read More
18
Nov
2024
In Vivo Gene Therapy Isn’t The Answer. Sickle Cell Patients Need Today’s Treatments
On his fourth birthday, Adamu couldn’t celebrate. The boy, from a rural village in Nigeria, had a flare up of his sickle cell disease known as a pain crisis. His parents tell me the rare days when he’s full of energy and playing with his friends feel like a precious gift. This year, he was given a cruel reminder of... Read More
14
Nov
2024
RFK Jr. to HHS. I Was Wrong
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Nov
2024
Save the Date: TR 10th Anniversary
Hard to believe, but the 10th Anniversary of Timmerman Report is coming up in March 2025. Time to party! The past 10 years of biotechnology have been remarkable. I’m fortunate. I’ve had a front-row seat to chronicle monumental advances at Timmerman Report, and occasionally influence events. Join me and a group of biotech leaders in Boston on Mar. 6 and... Read More
12
Nov
2024
Third Rock-backed Trace Neuroscience Debuts with $101M, RNA Drug for ALS
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Nov
2024
A Day to Thank Veterans
Happy Veteran’s Day. For some reason, this day doesn’t receive the same level of attention of most holidays on the American calendar. Let’s pause today to thank veterans in our communities. For real. Face to face. Or maybe on the phone. Not in a tweet. As I wrote last year: Today is a day when I honor my Dad. He... Read More
7
Nov
2024
What Will Trump Do? Look at the Record
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Nov
2024
Developing a New Class of RNA Therapeutics: Leslie Williams on The Long Run
Today’s guest on The Long Run is Leslie Williams. Leslie is the co-founder and CEO of Boston-based hC Bioscience. Her company is working to develop a new class of RNA medicines directed at transfer RNAs, also known as tRNA. The gist of the idea is to make these tRNA therapies, delivered with a lipid nanoparticle, that can carry instructions to... Read More
4
Nov
2024
Lessons from the Manure Digester
My first real journalism job flashed to mind this week. It was 1998. I was a kid reporter fresh out of the University of Wisconsin. My job was to cover Dane County government for The Capital Times, the progressive newspaper in Madison. Dane County had about 400,000 people. Half lived in the beating liberal heart of the City of Madison... Read More
4
Nov
2024
When Business and Politics Collide
I have always kept my business and political lives separate – and have had no trouble doing so. But now my political beliefs and my industry are threatened by the same plague. Donald Trump would not merely undermine our country, he would undermine the fundamental principle of our industry – and, speaking quite selfishly, my business…and yours. That principle is... Read More
31
Oct
2024
Aliada’s Mega Return, GSK & AbbVie Eye T-Cell Engagers, and IPO Scorecard
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Oct
2024
And Just Like That: What the Viral Adoption of a Clinical AI App Means for Pharma R&D
In 2011, we were experiencing the ascension of technologies like the cloud and the smartphone. Apps had become a thing: social network apps like Instagram (the iPhone “App of the Year” in 2011) and Twitter, utility apps like Evernote and Dropbox, navigation apps like Google Maps and Waze, and game apps like Angry Birds. Yet in medicine, as I wrote... Read More
30
Oct
2024
Archon Biosciences Gets $20M to Translate Nobel-Winning Science into Antibody ‘Cages’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2024
Intellia In Vivo Disappoints, Seaport Aims at Anxiety, & Wave Shows RNA Editing Promise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2024
Yes We Can: My Response To Skeptical Readers
Two weeks ago, I wrote about how difficult it is for R&D leaders to “pick winners,” despite the enormous incentives to do so. I explained how we tend to underestimate the role of chance, and overestimate our ability to “domesticate uncertainty,” as Nassim Taleb and I wrote in the Financial Times in 2008. Mostly, efforts to systematically improve success rates... Read More